Search - tctmd.com

Displaying 41 - 60 of 64

Sort: Relevancy | Date

Presentation TCT 2017

Emerging Thromboresistant BMS 2: Titanium-Nitride-Oxide Stents

Presenter: Julinda Mehilli, Giulio G. Stefanini, Pim A.L. Tonino

October 30, 2017

Presentation TCT 2017

Emerging Thromboresistant BMS 1: Cobra PzF Stents

Presenter: Julinda Mehilli, Giulio G. Stefanini, Donald Cutlip

October 30, 2017

Presentation TCT 2017

Should BMS Stay On the Shelf? Clinical and Global Perspectives on the Role Of BMS in 2017

Presenter: Julinda Mehilli, Giulio G. Stefanini, Raffaele Piccolo

October 30, 2017

Presentation TCT 2017

Debate: STEMI With Multivessel Disease - Staged (Culprit) Lesion Revascularization Followed by Noninvasive Risk Stratification Is Currently Indicated

Presenter: Jeroen J. Bax, Michael A. Borger, Stephan Windecker, Giulio G. Stefanini

October 29, 2017

Presentation TCT 2016

How to Evaluate and Treat the Patient With Metallic Stent Thrombosis: The Usual Suspects and Beyond

Presenter: Fernando Alfonso, Stephan Windecker, Giulio G. Stefanini

October 30, 2016

Presentation JIM 2016

The Synergy Stent: Optimal In Complex Patients

Presenter: Giulio G. Stefanini

February 10, 2016

News Conference News EuroPCR 2015

Trials Explore the Potential of Biodegradable-Polymer Stents

Caitlin E. Cox

May 21, 2015

Presentation TCT 2014

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Presenter: Mitchell W. Krucoff, Giulio G. Stefanini, Stephane Cook

September 16, 2014

Presentation TCT 2014

I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease

Presenter: Mitchell W. Krucoff, Giulio G. Stefanini, Bo Xu

September 16, 2014

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Presentation TCT 2014

TCT 599: Final Procedural, 30-Day and 6-Month Angiographic, Clinical, and OCT Outcomes from the DIRECT II Trial Using the Svelte Integrated Delivery System with Enzymatic Bioabsobable Sirolimus Coating

Presenter: Marie-Claude Morice, Giulio G. Stefanini, Pedro A. Lemos, Stefan Verheye

September 15, 2014

Presentation TCT 2014

Is Pro-healing a Valid Concept? The Sirolimus-Endothelial Progenitor Cell Antibody Combo Technology

Presenter: Marie-Claude Morice, Giulio G. Stefanini, Pedro A. Lemos, Michael Haude

September 15, 2014

Presentation TCT 2014

Hematologic Etiologies of Stent Thrombosis and How to Evaluate

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Giulio G. Stefanini

September 14, 2014

Presentation TCT 2014

How to Achieve BRS Distal Delivery Through Tortuous Calcified Lesions

Presenter: Antonio Colombo, Nicolas M. van Mieghem, Giulio G. Stefanini

September 14, 2014

News Daily News

Un Meta Análisis Confirma la Ventaja de los SLF de Última Generación en el Manejo de Cuadros de STEMI

Todd Neale

August 07, 2014

News Daily News

Meta-analysis Confirms Advantage of New-Generation DES in STEMI

Todd Neale

August 07, 2014

News Daily News

NEXT Published: Biodegradable Polymer BES Shows Noninferiority to EES

Yael L. Maxwell

May 08, 2013

News Daily News

NEXT Publicado: Los SLB de Polímero Biodegradable No son Inferiores a los SLE

Yael L. Maxwell

May 08, 2013

Presentation TCT 2013

Gender-based Analysis of Everolimus-Eluting Stent Safety in the Bern-Rotterdam Cohort

Presenter: Giulio Stefanini, Lorenz R?ber, Michael Magro, Bindu Kalesan, Masanori Taniwaki, Cihan Simsek, Peter Wenaweser, Ron Van Domburg, Bernhard Meier, Peter Juni, Patrick Serruys, Stephan Windecker

January 31, 2013

Presentation TCT 2013

The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated With The Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and Paclitaxel-Eluting...

Presenter: Aris Moschovitis, Giulio Stefanini, Michael Magro, Lorenz R?ber, Bindu Kalesan, Masanori Taniwaki, Joost Daemen, Peter Wenaweser, Ron Van Domburg, Bernhard Meier, Peter Juni, Patrick Serruys, Stephan Windecker

January 31, 2013

Advertisement

Emerging Thromboresistant BMS 2: Titanium-Nitride-Oxide Stents

Emerging Thromboresistant BMS 1: Cobra PzF Stents

Should BMS Stay On the Shelf? Clinical and Global Perspectives on the Role Of BMS in 2017

Debate: STEMI With Multivessel Disease - Staged (Culprit) Lesion Revascularization Followed by Noninvasive Risk Stratification Is Currently Indicated

How to Evaluate and Treat the Patient With Metallic Stent Thrombosis: The Usual Suspects and Beyond

The Synergy Stent: Optimal In Complex Patients

Trials Explore the Potential of Biodegradable-Polymer Stents

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

TCT 599: Final Procedural, 30-Day and 6-Month Angiographic, Clinical, and OCT Outcomes from the DIRECT II Trial Using the Svelte Integrated Delivery System with Enzymatic Bioabsobable Sirolimus Coating

Is Pro-healing a Valid Concept? The Sirolimus-Endothelial Progenitor Cell Antibody Combo Technology

Hematologic Etiologies of Stent Thrombosis and How to Evaluate

How to Achieve BRS Distal Delivery Through Tortuous Calcified Lesions

Un Meta Análisis Confirma la Ventaja de los SLF de Última Generación en el Manejo de Cuadros de STEMI

Meta-analysis Confirms Advantage of New-Generation DES in STEMI

NEXT Published: Biodegradable Polymer BES Shows Noninferiority to EES

NEXT Publicado: Los SLB de Polímero Biodegradable No son Inferiores a los SLE

Gender-based Analysis of Everolimus-Eluting Stent Safety in the Bern-Rotterdam Cohort

The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated With The Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and Paclitaxel-Eluting...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content